Showing results (61-70 of 73) with videos related to
Sort By:
Pageof 8
Journal for Immunotherapy of Cancer|December 14, 2023
Early kinetics of C reactive protein for cancer-agnostic prediction of therapy response and mortality in patients treated with immune checkpoint inhibitors: a multicenter cohort studyDominik A Barth, Florian Moik, Sarah Steinlechner, et al.Journal of Cancer Research and Clinical Oncology|December 30, 2025
Subgroup analyses of the phase 3 FOCUS study of melphalan/hepatic delivery system in patients with unresectable metastatic uveal melanomaJonathan S Zager, Marlana Orloff, Pier Francesco Ferrucci, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 12, 2023
First-Line, Fixed-Duration Nivolumab Plus Ipilimumab Followed by Nivolumab in Clinically Diverse Patient Populations With Unresectable Stage III or IV Melanoma: CheckMate 401Reinhard Dummer, Pippa Corrie, Ralf Gutzmer, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|May 7, 2025
Switching PD-1 to BRAF + MEK inhibition improves recurrence-free survival in patients receiving a second course of adjuvant melanoma therapyKatharina Schumann, Kai Christian Klespe, Cornelia Mauch, et al.Annals of Surgical Oncology|April 7, 2025
An Open-label, Randomized Study of Melphalan/Hepatic Delivery System Versus Best Alternative Care in Patients with Unresectable Metastatic Uveal MelanomaJonathan S Zager, Marlana Orloff, Pier Francesco Ferrucci, et al.Annals of Surgical Oncology|May 4, 2024
Efficacy and Safety of the Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter Phase 3 StudyJonathan S Zager, Marlana Orloff, Pier Francesco Ferrucci, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 2022
Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated <i>BRAF</i>-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II TrialPaolo A Ascierto, Mario Mandalà, Pier Francesso Ferrucci, et al.Journal for Immunotherapy of Cancer|February 4, 2025
Phase I study of intratumoral administration of CV8102 in patients with advanced melanoma, squamous cell carcinoma of the skin, squamous cell carcinoma of the head and neck, or adenoid cystic carcinomaThomas Eigentler, Ioannis Thomas, Igor Samoylenko, et al.Journal for Immunotherapy of Cancer|May 14, 2021
Pretreatment metastatic growth rate determines clinical outcome of advanced melanoma patients treated with anti-PD-1 antibodies: a multicenter cohort studyNikolaus B Wagner, Max M Lenders, Kathrin Kühl, et al.NEJM Evidence|September 24, 2024
Sequencing of Checkpoint or BRAF/MEK Inhibitors on Brain Metastases in MelanomaPaolo A Ascierto, Mario Mandalà, Pier Francesco Ferrucci, et al.Pageof 8